August 18, 2023 11:21 AM EDT

Merck's Welireg meets co-primary endpoint in kidney cancer PhIII; Noveome raises half of planned $40M VC round

Paul Schloesser

Associate Editor

Tyler Patchen

News Reporter

Merck said Friday morning that its HIF-2α inhibitor Welireg met the co-primary endpoint of progression-free survival in a Phase III trial for patients with advanced …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Merck's Welireg meets co-primary endpoint in kidney cancer PhIII; Noveome raises half of planned $40M VC round

Paul Schloesser

Associate Editor

Tyler Patchen

News Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Pfizer CEO says opportunities with Trump ‘clearly outweigh’ the risks for pharma

Trump blog: Judge extends nationwide block on NIH payment cuts

RFK Jr. readies review of childhood vaccine schedule after pledging not to

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Mer­ck­'s Welireg meets co-pri­ma­ry end­point in kid­ney can­cer PhI­II; Noveome rais­es half of planned $40M VC round

Associate Editor

News Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Merck's Welireg meets co-primary endpoint in kidney cancer PhIII; Noveome raises half of planned $40M VC round